Physician
Oncology
Dr. Iain J. Webb, MD
|
|
Give Review
Iain J. Webb, MD practices Oncology. Iain Webb is a published doctor. He published 30 publications, including: 'Adenovirus vector-based purging of multiple myeloma cells.'
Publications
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castratio...
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
- Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
- Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patien...
- Antibody-based therapeutics: focus on prostate cancer.
- Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augm...
- Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
- Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients ...
- Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.
- Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
- Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
- Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in ne...
- Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
- Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarco...
- T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
- In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.
- Adenovirus vector-based purging of multiple myeloma cells.
- Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic prog...
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
- Risks, costs, and alternatives to platelet transfusions.
- Anti-estrogens induce apoptosis of multiple myeloma cells.
- Predictors of high yield and purify of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma.
- Transfusion support in acute leukemias.
- Umbilical cord blood as a source of progenitor cells to reconstitute hematopoiesis.
- Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering.
- Sequential CD34+ and CD4+ cell selection from leukapheresis components.
- The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors t...
Schools
McGill University Faculty of Medicine
St Michaels Hospital
Montreal Gen Hospital
Beth Israel Hospital
McGill University
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Beth Israel Deaconess Medical Center -
McGill University Faculty of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Rebecca S. Heist, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. William G. Kaelin Jr., MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jens G. Lohr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Lathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marios Giannakis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey R. Oxnard, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Frank S. Hodi Jr., MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Peter C. Enzinger, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Simon Khagi, MD
This Doctor is OpenDoctor Recommended.
|